New antibody shot tested to shield vulnerable babies from dangerous RSV
NCT ID NCT06710925
Summary
This study tested whether a new antibody injection called TNM001 could prevent serious lung infections caused by Respiratory Syncytial Virus (RSV) in high-risk infants. About 315 infants under 1 year old entering their first RSV season received either the antibody or a placebo shot and were followed for 9 months. The goal was to see if the antibody safely reduced the number of babies needing medical care for RSV-related breathing problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Chongqing Medical University
Chongqing, Sichuan, 404100, China
-
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.